#marineviralspecies; #journalCell, #ScienceXNewsletter; #polarcircle; #TaraOcean; #OhioStateUniversity; #biodiversityhotspot; #ArcticOcean; #climatechange; #biogeochemistry
United States, Apr 26 (Canadian-Media): An international team of scientists were able to identify nearly 200,000 marine viral species, according to the findings which appeared on April 25 in the journal Cell, Science X Newsletter reports said.
These findings help create a new picture of our planet and how it may be impacted by interactions among organisms and point to issues ranging from evolution to climate change.
Image Credit: A. Deniaud Garcia/ Fondation Tara Ocean: The Tara sailing on its Polar Circle expedition in 2013.
"Viruses are these tiny things that you can't even see, but because they're present in such huge numbers, they really matter," says senior author Matthew Sullivan, a microbiologist at the Ohio State University. "We've developed a distribution map that is foundational for anyone who wants to study how viruses manipulate the ecosystem. There were many things that surprised us about our findings."
Among the surprises was the existence of these nearly 200,000 marine viral species. Additionally, meta-community analysis showed that the viruses were organized into five distinct ecological zones throughout the entire ocean, which was unexpected given the fluid nature of the oceans and the complexity of many of the marine regions. Also, despite the paradigm from larger organisms that species diversity is highest near the equator and lowest near the poles, the researchers collected an extensive number of samples in the Arctic compared to previous studies of ocean life and found a biodiversity hotspot in the Arctic Ocean.
The samples were collected between 2009 and 2013 on the Tara as part of the Tara Oceans effort. Begun in 2006, the Tara project aims to conduct unique and innovative ocean science with the goal of predicting and better anticipating the impacts of climate change. In the current effort, a rotating team of scientists spent time on the boat collecting ocean water samples from different depths across many geographical regions. After being collected, the samples for this study were filtered and shipped back to about a dozen different labs for analysis.
The investigators studied not only the water samples for viruses, but also other microbes and other living creatures. "We filtered the samples to analyze organisms ranging in size from viruses to fish eggs," Sullivan says. He adds that papers reporting some of the other microbial components from the samples are forthcoming.
Another noteworthy aspect of the project was the extensive number of samples collected in the Arctic, a highlight that has not been part of earlier studies of ocean life.
Image Credit: A. Deniaud/Fondation Tara Ocean: Samples being collected on the Tara.
This research has significant implications for understanding how ocean microorganisms affect the earth's atmosphere. "In the last 20 years or so, we've learned that half of the oxygen that we breathe comes from marine organisms," Sullivan notes. "Additionally, the oceans soak up half of the carbon dioxide from the atmosphere."
"Because of complex chemistry, increased levels of carbon dioxide at the surface acidify the oceans," Sullivan adds. "However, if carbon dioxide instead is converted to organic carbon and biomass, then it can become particulate and sink into the deep oceans. That's a good result for helping mitigate human-induced climate change—and we're learning that viruses can help facilitate this sinking. Having a new map of where these viruses are located can help us understand this ocean carbon "pump" and, more broadly, biogeochemistry that impacts the planet."
The investigators say that having a more complete picture of marine viral distribution and abundance will help them to determine which viruses they should be focusing on for further studies. Additionally, the maps based on this research establish a baseline for other collection efforts going forward, which can help to answer questions about how levels of microorganisms change over time, in response to both seasonal variation and climate change.
"Previous ocean ecosystem models have commonly ignored microbes, and rarely included viruses, but we now know they are a vital component to include," Sullivan concludes.
#Alzheimer; #amyloidprecursorprotein; #pathologicalcontributors; #aging; #Abeta; #synapticdysfunction;
Florida (US), Apr 24 (Canadian-Media): Worldwide, 50 million people are living with Alzheimer's disease and other dementias and every 65 seconds someone in the United States develops this disease, which causes problems with memory, thinking and behavior, Florida's Alzheimer's Association reports said.
Image Credit: Qi Zhang, Ph.D. and Claire E. DelBove/The background is an image of neurons (blue). Some of them express the new amyloid precursor protein reporter (green) and a synapse-marker, Synaptophysin-pHTomato (red). The rendering at the lower left corner illustrates the Alzheimer's disease etiology model derived from the study, in which a variety of pathological contributors like aging and Abeta converge on presynaptic cholesterol and the disruption of cholesterol homeostasis diverges to various pathological outcomes like synaptic dysfunction and neuronal loss.
It has been more than 100 years since Alois Alzheimer, M.D., a German psychiatrist and neuropathologist, first reported the presence of senile plaques in an Alzheimer's disease patient brain. It led to the discovery of amyloid precursor protein that produces deposits or plaques of amyloid fragments in the brain, the suspected culprit of Alzheimer's disease. Since then, amyloid precursor protein has been extensively studied because of its association with Alzheimer's disease. However, amyloid precursor protein distribution within and on neurons and its function in these cells remain unclear.
A team of neuroscientists led by Florida Atlantic University's Brain Institute sought to answer a fundamental question in their quest to combat Alzheimer's disease—"Is amyloid precursor protein the mastermind behind Alzheimer's disease or is it just an accomplice?"
Mutations found in amyloid precursor protein have been linked to rare cases of familial Alzheimer's disease. Although scientists have gained a lot knowledge about how this protein turns into amyloid plaques, little is known about its native function in neurons. In the case of more common sporadic Alzheimer's disease, the highest genetic risk factor is a protein that is involved in cholesterol transportation and not this amyloid precursor protein. Moreover, various clinical trials designed to address Alzheimer's disease by minimizing amyloid plaque formation have failed, including one from Biogen announced last month.
In a study published in the journal Neurobiology of Disease, Qi Zhang, Ph.D., senior author, an investigator at the FAU Brain Institute, and an assistant research professor in FAU's Schmidt College of Medicine, along with collaborators from Vanderbilt University, tackle this Alzheimer's disease mystery by devising a multi-functional reporter for amyloid precursor protein and tracking the protein's localization and mobility using quantitative imaging with unprecedented accuracy.
For the study, Zhang and collaborators genetically disrupted the interaction between cholesterol and amyloid precursor protein. Surprisingly, by disengaging the two, they discovered that this manipulation not only disrupts the trafficking of amyloid precursor protein but also messes up cholesterol distribution at the neuronal surface. Neurons with an altered distribution of cholesterol exhibited swollen synapses and fragmented axons and other early signs of neurodegeneration.
"Our study is intriguing because we noticed a peculiar association between amyloid precursor protein and cholesterol that resides in the cell membrane of synapses, which are points of contact among neurons and the biological basis for learning and memory," said Zhang. "Amyloid precursor protein may just be one of the many accomplices partially contributing to cholesterol deficiency. Strangely, the heart and brain seem to meet again in the fight against bad cholesterol."
Given the broad involvement of cholesterol in almost all aspects of neurons' life, Zhang and collaborators have proposed a new theory about the amyloid precursor protein connection in Alzheimer's disease, especially in the surface of those tiny synapses, which triggers neurodegeneration.
"Although still in early stages, this cutting-edge research by Dr. Zhang and his collaborators at Vanderbilt University may have implications for the millions of people at risk for or suffering with Alzheimer's disease," said Randy D. Blakely, Ph.D., executive director of the FAU Brain Institute and a professor of biomedical science in FAU's Schmidt College of Medicine. "The number of people in Florida alone who are age 65 and older with Alzheimer's disease is expected to increase 41.2 percent by 2025 to a projected 720,000, highlighting the urgency of finding a medical breakthrough."
Locally, Alzheimer's disease affects 11.5 percent of Medicare beneficiaries in Palm Beach County and 12.7 percent of Medicare beneficiaries in Broward County (a nearly 18 percent increase over national average).
According to the Alzheimer's Association, Florida is number one in per capita cases of Alzheimer's disease in the U.S.
#geneediting; #CRISPR-Cas9; #research; #ArizonaStateUniversity; #ScienceXNewsletter; #guideRNA; #genedrives;
Arizona (US), Apr 24 (Canadian-Media): A method of rendering the gene editing tool CRISPR-Cas9 "immunosilent," potentially allowing the editing and repair of genes to be accomplished reliably and stealthily has been described in research appearing in the advanced online edition of the journal Nature Communications, Karen Andersen, Samira Kiani and their colleagues at Arizona State University, Science X Newsletter reported.
Image Credit: Jason Drees/The graphic illustrates the technique described in the new study. A version of the Cas9 protein used in CRISPR gene editing has been mutated. While this protein, seen in blue, retains its proper functioning, it remains "immunosilent"--hidden from predation as a foreign entity by the immune system's T cells (seen in brown).
The study is the first to accurately predict the dominant binding sites or epitopes responsible for immune recognition of the Cas9 protein and experimentally target them for modification. The findings bring CRISPR a step closer to safe, clinical application.
The advance of science is something like the wandering of an explorer through an uncharted jungle. Often, the dense undergrowth can seem impenetrable, but at certain privileged moments, a clearing opens, and an entirely new landscape emerges.
Something like this is occurring in the field of biology with the recent discovery of powerful techniques for intervening in the genetic code of life. A new method for editing genes with the ease of a computer's cut-and-paste functions may prove more momentous than the splitting of the atom and represents a major advance in the war against deadly diseases.
The breakthrough—known as CRISPR—has been greeted with ecstatic optimism and grave apprehension.
Anderson is a professor in the Biodesign Virginia G. Piper Center for Personalized Diagnostics and ASU's School of Life Sciences. She is also associate professor of medicine at the Mayo Clinic Arizona. Kiani recently joined the Biodesign Institute in addition to her appointments at ASU's School of Life Sciences and the School of Biological and Health Systems Engineering. Her research interests include the use of synthetic biology methods to improve CRISPR safety.
Ancient tool, futuristic science
Back in 1987, a team of researchers in Osaka, Japan found something peculiar. Identical genetic sequences appeared to be cropping up repeatedly in the bacterial genome of E. coli. These palindromic sequences were separated by abbreviated snippets of DNA of varying composition.
The nature of these strange repeated sequences and the curious DNA phrases separating them were an enigma. Remarkably, they started showing up in other bacteria. Indeed, the phenomenon seemed to be ubiquitous, and the race for an explanation was on.
Today we know that the researchers had stumbled on a previously unknown bacterial immune system—CRISPR (for clustered regularly interspaced short palindromic repeats).
CRISPR relies on two primary components. The first, known as a guide RNA, is a sort of molecular bloodhound, responsible for locating a particular site in the genome to be modified or disabled. The second component, known as Cas9, is a special type of protein known as an endonuclease. It functions like a pair of razor-sharp pruning shears, cutting through the double stranded DNA at the desired site located by the guide RNA
Clever researchers soon recognized the potential of CRISPR-Cas9 to serve as an all-purpose gene editing tool, useful not only for modifying selected regions throughout the entire bacterial genome, but the genomes of all living organisms, including humans. The possibilities are staggering and are not limited to effective treatments for a broad range of genetic diseases. For the first time, it may be possible to correct Nature's genetic typos, curing many of these diseases outright and preventing others from ever arising.
CRISPR also holds the potential to radically transform ecosystems and has been suggested as a means of wiping out diseases like malaria by driving the mosquitos that carry them to extinction, through CRISPR-aided techniques known as gene drives.
When a bacterium like E. coli is invaded by an unfamiliar virus—known as a bacteriophage—the CRISPR system is activated. If bacterial defense mechanisms successfully disable the virus, CRISPR chops the invader's DNA into pieces and stores these fragments in a kind of genomic library. A subsequent viral assault on the bacterium will cause CRISPR to compare DNA segments of the offending virus with the bacterium's data bank of DNA fragments from previous viral attacks. When the guide RNA finds a match along the virus' DNA, it binds with the complementary sequence and the Cas9 protein severs the DNA, terminating the virus.
For the first time in earth's history, one species holds the key to directing the course of its own evolution, (not to mention the evolution of bacteria, giraffes, redwood trees and all planetary life). Currently, there are prohibitions on gene editing efforts in humans that could be passed through the germline to successive generations, but in at least one case, these boundaries have been ominously overstepped. So powerful and versatile is the CRISPR method, there are likely few domains of applied biology that will remain untouched by it.
But before CRISPR can take its first tentative steps in the clinic, a number of safety issues must be addressed, beginning with the gene-slicing protein Cas9.
"Being as much a societal revolution as a technological revolution, many researchers have started to look into ethical, societal, safety and regulatory considerations related to CRISPR usage,"Kiani says. "Safety engineering to address controllability, specificity and side effects of CRISPR treatments have gained significant momentum and ethical debates have arisen to ensure correct use of technology. My lab is interested to address both issues."
Cas9 is a precise and versatile tool, replacing early, inaccurate and inefficient gene editing techniques with a rapid, inexpensive and deadly-accurate cutting device. But Cas9 in its native form may not be well tolerated by the human body.
Making CRISPR technology safe for clinical use is a central concern and the issue is challenging. One necessity is to ensure that the central machinery of CRISPR is not recognized by a patient's immune system as a foreign entity and attacked. An immune response of this kind could cause significant toxicity. (An early, pre-CRISPR method of introducing altered genes to correct a rare genetic disorder resulted in tragedy when an immune system revolt caused multiple organ failure and death. Today, improved vectors for gene therapy have resulted in safer treatments for a range of genetic disorders, though "off-target" effects of these interventions remain an important concern.)
The Cas9 protein is derived from a common bacterium, streptococcus pyogenes. "The problem," Anderson says, "is that many of us are already immune to streptococcus. If you have had a Group A strep infection, you may have preexisting immunity to that protein."
S. pyogenes is a round bacterium that commonly colonizes the throat, genital mucosa, rectum and skin, affecting 700 million people annually worldwide. It is responsible for diseases ranging from rheumatic fever and rheumatic heart disease to scarlet fever and streptococcal pharyngitis—commonly known as strep throat.
In previous gene editing efforts, cells were removed from human tissue, reengineered and replaced in the body. The power of CRISPR allows researchers to modify DNA within a living person's tissue and even to target multiple gene modifications with a single CRISPR intervention. "If you want to think about repairing cells that are in an organ, like a liver cell or kidney or brain," Anderson says, "then you have to express the bacterial protein there." This is where the threat of triggering an immune response to Cas9 becomes a formidable obstacle.
Cas9 goes incognito
The new study affirms that Cas9 is indeed immunogenic in humans and that preexisting exposure to S. pyogenes can drive the body's T cells to launch an immune attack against the bacterial protein. When 143 samples of blood were screened, 82 of them (or 57.3 percent) showed detectable levels of antibody to S. pyogenes.
The study next describes an effort to produce a fully functional version of Cas9, suitable for gene editing, which is not recognized and targeted by the immune system. To do this, the researchers identified the regions of antibody binding on the Cas9 molecule, (known as epitopes), that were directly implicated in triggering T cell recognition and attack.
Two mutations in so-called anchor residues of the Cas9 epitope were explored individually and in combination to assess their effect on immunogenicity. Modifying these regions by just a single amino acid produced a version of Cas9 that could operate undercover. T-cell reactivity to the mutated peptide showed a 25-30 fold reduction, while leaving Cas9's DNA-cutting ability intact.
"That's the unique part of what we've done," Anderson says. "We took those dominant epitopes and tried to silence them—just by doing one or two mutations in the Cas9 gene. But we rebuilt it, so the gene was still functional. It's not immunologically silent, but its more quiet." Indeed, the study results confirmed that in cultured cells, the reengineered Cas9 was less immunologically active, while retaining its functional properties. The author's stress that the technique could be combined with other strategies to further improve CRISPR safety and reduce the need for immunosuppressant drugs.
Exciting new avenues of research are being explored that would enable CRISPR to be used to induce epigenetic changes, turning on silent genes, altering the activity of disrupted genes or otherwise modifying gene expression without permanent changes to the DNA. Such interventions will require the CRISPR system to remain much longer in the body to be effective, perhaps weeks or months. Here, potential immunity to Cas9 will be even more of a critical consideration. Custom tailoring of epitopes to silence the immune response to Cas9 offers an attractive approach.
"We are hoping that this study is the beginning of many efforts that when combined can address the immunogenicity of CRISPR for clinical trials," Kiani says.
#Irvine study; #mediaviolenece; #mediaexposure; #ScienceAdvances
New York, Apr 23 (Canadian-Media): Repeated exposure to media coverage of collective traumas, such as mass shootings or natural disasters, can fuel a cycle of distress, according to a University of California, Irvine study.
Researchers found that individuals can become more emotionally responsive to news reports of subsequent incidents, resulting in heightened anxiety and worry about future occurrences.
The report appears in Science Advances, a peer-reviewed, multidisciplinary, open-access journal published by the American Association for the Advancement of Science.
“It’s natural for people to experience feelings of concern and uncertainty when a terrorist attack or a devastating hurricane occurs,” said senior author Roxane Cohen Silver, UC Irvine professor of psychological science. “Media coverage of these events, fueled by the 24-hour news cycle and proliferation of mobile technologies, is often repetitious and can contain graphic images, video and sensationalized stories, extending the impact to populations beyond those directly involved.”
Earlier research has shown that consumption of media coverage of a collective trauma is a rational response for individuals seeking information as a way to mitigate their apprehension and cope with their stress. However, this strategy may backfire. According to this new study, repeated exposure to explicit content may exacerbate fear about future adversities, which promotes future media consumption and greater anxiety when they do occur. There is an even greater risk of falling into this pattern for those who have experienced violence in their lives or have been diagnosed with mental health ailments.
“The cycle of media exposure and distress appears to have downstream implications for public health as well,” said Rebecca R. Thompson, a UC Irvine postdoctoral scholar in psychological science and lead author of the report. “Repeated exposure to news coverage of collective traumas has been linked to poor mental health consequences — such as flashbacks — in the immediate aftermath and posttraumatic stress responses and physical health problems over time, even among individuals who did not directly experience the event.”
A national longitudinal study of more than 4,000 U.S. residents was conducted by Thompson, Silver and their colleagues over a three-year period following the 2013 Boston Marathon bombings and the 2016 massacre at the Pulse nightclub in Orlando, Florida. Participants were surveyed four times, enabling the team to capture responses to both tragedies and examine how responses to the first incident affected reactions to news coverage of the second.
“Our findings suggest that media organizations should seek to balance the sensationalistic aspects of their coverage, such as providing more informational accounts as opposed to lengthy descriptions of carnage, as they work to inform the public about breaking news events,” Silver said. “This may lessen the impact of exposure to one event, reducing the likelihood of increased worry and media-seeking behavior for subsequent events.”
Also conducting the study were Nickolas M. Jones, former UC Irvine psychological science doctoral student, and E. Alison Holman, UC Irvine associate professor of nursing. Project funding was provided by National Science foundation grants BCS-1342637, BCS-385 1451812 and BCS-1650792.
Medicaid could save $2.6 billion within a year if just 1 percent of recipients quit smoking: UCSF research study
#Medicaid; #UniversityofCalofrniaSanFrancisco; #JAMANetworkOpen'
New York, Apr 23 (Canadian-Media) Reducing smoking, and its associated health effects, among Medicaid recipients in each state by just 1 percent would result in $2.6 billion in total Medicaid savings the following year, according to new research by UC San Francisco.
The median state would save $25 million, ranging from $630.2 million in California (if the smoking rate dropped from 15.5 percent to 14.5 percent) to $2.5 million in South Dakota (if the rate dropped from 41.3 to 40.3 percent), the research found.
The study, by Stanton A. Glantz, PhD, director of the UCSF Center for Tobacco Control Research and Education -- University of California, San Francisco -- is published April 12, 2019 in JAMA Network Open.
“While 14 percent of all adults in the U.S. smoke cigarettes, 24.5 percent of adult Medicaid recipients smoke,” said Glantz. “This suggests that an investment in reducing smoking in this population could be associated with a reduction in Medicaid costs in the short run.”
Total Medicaid costs in 2017 were $577 billion.
“There is no question that reducing smoking is associated with reduced health costs, but it’s commonly assumed that it takes years to see these savings, which has discouraged many states from prioritizing helping smokers quit,” said Glantz.
“While this is true for some diseases, such as cancer, other health risks such as heart attacks, lung disease and pregnancy complications respond quickly to changes in smoking behavior. So reducing the prevalence of smoking would be an excellent short-term investment in the physical health of smokers and the fiscal health of the Medicaid system,” he said.
Glantz derived state-by-state percentages of Medicaid recipients who smoke based on data from the 2017 Behavioral Risk Factors Surveillance System, which provides the percentage of smokers among the population of each state, and the 2017 National Health Interview Survey, which identifies Medicaid recipients in four major regions in the United States (Northeast, Midwest, South and West).
He then estimated potential Medicaid savings based on a previous research finding which showed that a 1 percent relative reduction in smoking prevalence is associated with a reduction of 0.118 percent in per capita health care spending.
Glantz noted that the study looked only at the potential savings from reducing the total number of Medicaid recipients who smoke. But even if each smoker just smoked less, there would be additional reductions in health care costs, he said.
Cost reductions from reducing smoking would continue and likely grow over the long term.
“Because some health risks linked with smoking, such as cancer, can take years to fully manifest, these savings would be likely to grow with each passing year,” Glantz said.
The paper shows predicted reductions in Medicaid costs by each state.